Nifedipine gastrointestinal therapeutic system - Hypertension management to improve cardiovascular outcomes

International Journal of Clinical Practice

Volumn 59, Issue 9, 2005, Pages 1112-1119

  Heagerty, Anthony M ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Calcium channel blocker; Cardiovascular disease; Hypertension; Nifedipine GITS; Outcomes; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIVITAMIN K; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC GLYCOSIDE; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; NIFEDIPINE; NITRATE; PERINDOPRIL; PLACEBO; SOTALOL; TRANDOLAPRIL; VERAPAMIL; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; HEADACHE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOKALEMIA; KIDNEY DYSFUNCTION; META ANALYSIS; METABOLIC DISORDER; PERIPHERAL EDEMA; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADULT; AGED; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NIFEDIPINE; RANDOMIZED CONTROLLED TRIALS;

EID: 33644841614     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00670.x     Document Type: Article

References (56)

1. Cherry DK, Burt CW, Woodwell DA. National Ambulatory Medical Care Survey: 2001 summary. Adv Data 2003; 1-44.
2. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-92.
3. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-1252.
4. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-9.
5. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.
6. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
7. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-10.
8. Kannel WB. Progression of uncontrolled hypertension and implications for managing its sequelae. Manag Care 2003; 12: 26-33.
9. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood pressure lowering treatment trialists' collaboration. Lancet 2000; 356: 1955-64.
10. Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-7.
11. Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society 2004-BHSIV. 2004; 18: 139-85.
12. Cifkova R, Erdine S, Fagard R et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21: 1779-86.
13. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
14. Jackson R, Lawes CM, Bennett DA et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365: 434-41.
15. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
16. European Society of Hypertension and European Society of Cardiology. 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
17. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-72.
18. Gong L, Zhang W, Zhu Y et al. Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens 1996; 14: 1237-45.
19. Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet 1999; 354: 1751-6.
20. Liu L, Wang JG, Gong L et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic hypertension in China (Syst-China) collaborative group. J Hypertens 1998; 16: 1823-9.
21. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigator. Lancet 1997; 350: 757-64.
22. Mancia G, Omboni S, Parati G. Twenty-four hour ambulatory blood pressure in the international nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT). J Hypertens 2002; 20: 545-53.
23. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.
24. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20: 1461-4.
25. Mancia G, Ruilope L, Palmer C et al. Effects of nifedipine GITS and diuretics in isolated systolic hypertension -a subanalysis of the INSIGHT study. Blood Press 2004; 13: 310-5.
26. Joint British Societies' Cardiac Risk Assessor Computer Program (retrieved from http://www.hyp.ac.uk/bhs/risk.xls).
27. Motro M, Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001; 37: 1410-3.
28. Simon A, Gariepy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001; 103: 2949-54.
29. Van Bortel LM. What does intima-media thickness tell us? J Hypertens 2005; 23: 37-9.
30. O'Leary DH, Polak JF, Kronmal RA et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. N Engl J Med 1999; 340: 14-22.
31. Zanchetti A, Rosei EA, Dal Palu C et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667-76.
32. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 2000; 102: 1503-10.
33. Verhaar MC, Honing ML, van Dam T et al. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res 1999; 42: 752-60.
34. ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: The ENCORE I study (Evaluation of Nifedipine and Cerivastatin On Recovery of Coronary Endothelial function). Circulation 2003; 107: 422-8.
35. Carlier SG. Hotline session. ENCORE II: The long-term effect of nifedipine on vasomotion and vessel morphology in patients with coronary artery disease: An intravascular ultrasound-assisted evaluation oral presentation European Society of Cardiology Congress; Munich, Germany; 28 August - 1 September 2004.
36. Lichtlen PR, Hugenholtz PG, Rafflenbeul W et al; INTACT Group Investigators. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990; 335: 1109-13.
37. Poole-Wilson PA, Lubsen J, Kirwan BA et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): Randomised controlled trial. Lancet 2004; 364: 849-57.
38. Lubsen J, Wagener G, Kirwan BA et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: The ACTION trial. J Hypertens 2005; 23: 641-8.
39. EUROASPIRE Study Group. EUROASPIRE (European Action on Secondary Prevention through Intervention to Reduce Events). A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569-82.
40. EUROASPIRE II Study Group Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro heart survey programme. Eur Heart J 2001; 22: 554-72.
41. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.
42. Pahor M, Guralnik JM, Corti MC et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191-7.
43. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5.
44. Lenfant C. The calcium channel blocker scare. Lessons for the future. Circulation 1995; 91: 2855-6.
45. Opie LH. Risks and benefits of calcium antagonists. Lancet 1995; 346: 961.
46. Opie LH, Messerli FH. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995; 92: 1068-73.
47. Horton R. Spinning the risks and benefits of calcium antagonists. Lancet 1995; 346: 586-7.
48. Furberg CD, Pahor M, Psaty BM. The unnecessary controversy. Eur Heart J 1996; 17: 1142-7.
49. Furberg CD, Psaty BM. Corrections to the nifedipine meta-analysis. Circulation 1996; 93: 1475-6.
50. Pahor M, Guralnik JM, Furberg CD et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347: 1061-5.
51. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.
52. The EUROPA Trail Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 342: 782-8.
53. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents in patients with coronary disease and normal blood pressure. The CAMELOT study: A randomized controlled trial. JAMA 2004; 292: 2217-26.
54. ALLHAT Officers. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-lowering Treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
55. Messerli FH. Race at ASCOT coming to a halt. Curr Hypertens Rep 2005; 7: 163-4.
56. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: Beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253-61.